GENE ONLINE|News &
Opinion
Blog

2021-08-11| Special

Novel Triple Immunotherapy Combo Rekindles Hope for Pancreatic Cancer Patients

by Isha Kapoor
Share To
Pancreatic cancer is the third-leading cause of cancer-related deaths in the US. Despite mammoth advancements in improving chemotherapeutic regimens, metastatic pancreatic adenocarcinomas still pose a greater clinical challenge due to dismal prognosis. However, MIT researchers now develop a novel triple immunotherapy combo that could potentially shrink or even eliminate pancreatic tumors.

GO Prime with only $1.49 now

SUBSCRIBE NOW
LATEST
Kite’s Yescarta Yields a Success in a Phase 3 Trial for Treating Large B-Cell Lymphoma
2023-03-22
Transcenta Announces First Patient Dosed in the U.S. Study of Its First-In-Class Gremlin1 Targeting Antibody TST003 for the Treatment of Solid Tumors
2023-03-22
Biogen’s Tofersen May Show Clinical Benefit in ALS Patients with Rare SOD1 Mutations
2023-03-21
Comparing ESG Regulations in the U.S., the U.K., and the EU
2023-03-21
See-Mode Technologies Secures Regulatory Approvals for its AI-powered Software that Automatically Analyses and Reports Breast & Thyroid Ultrasound Scans in Australia and New Zealand
2023-03-21
OncoC4 Bags $200 Million In CTLA-4 Antibody Pact With BioNTech
2023-03-21
HHS Issues Initial Guidance on Negotiation Program as Government’s Latest Move to Reduce Drug Prices
2023-03-21
READ MORE
EVENT
2023-03-28
Reuters Events: Pharma USA 2023
Philadelphia, USA
2023-04-24
Cell & Gene Therapy Summit 2023
Brussels, Belgium
2023-04-28
Boston Chinese Investment Club 2023 Biotech Pitch Competition
Boston, USA
2023-11-16
3rd INTERNATIONAL CONFERENCE ON NUTRITION AND HEALTHCARE
Dubai, UAE
SEE MORE
Newsletter

Subscribe to receive updates.

SIGN UP
Facebook
Youtube
Twitter
Linkedin
About
Explore
More
© 2023 GeneOnline
Privacy Policy | Terms of Service
Privacy Policy | Terms of Service
  • Subscribe to our newsletter and dive into the world of biopharma with us.
SIGN UP
x
Scroll to Top